A Multi-center, Randomized, Double-blind, Double Dummy, Placebo and Active Controlled Crossover Study, to Investigate the 24 Hour FEV1 Profile of a Single Dose of QMF TWISTHALER Device in Adult Patients With Persistent Asthma using fluticasone propionate/salmeterol (250/50 μg b.i.d.) as an active control.

Trial Profile

A Multi-center, Randomized, Double-blind, Double Dummy, Placebo and Active Controlled Crossover Study, to Investigate the 24 Hour FEV1 Profile of a Single Dose of QMF TWISTHALER Device in Adult Patients With Persistent Asthma using fluticasone propionate/salmeterol (250/50 μg b.i.d.) as an active control.

Completed
Phase of Trial: Phase II

Latest Information Update: 11 Oct 2014

At a glance

  • Drugs Indacaterol/mometasone (Primary) ; Salmeterol/fluticasone propionate
  • Indications Asthma
  • Focus Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 11 Oct 2014 New source identified and integrated (European Clinical Trials Database record: EudraCT2007-003192-39)
    • 20 Mar 2013 Actual end date changed from Jun 2008 to Apr 2008 as reported by ClinicalTrials.gov.
    • 08 Apr 2009 Actual patient number (37) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top